StoryTest
Rubedo doses first patient with RLS-1496 in Phase 1 trial in Europe, the world's first GPX4 modulator in humans
Rubedo Life Sciences announced the first patient dosed with RLS-1496 in a Phase 1 clinical trial in Europe. The trial evaluates safety, tolerability and clinical effects of topical RLS-1496 in patients with plaque psoriasis, atopic dermatitis and photoaged skin.